🔎 Trials Near Me

Utama › Neuroblastoma › California

Kajian klinikal Neuroblastoma di California

14 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Kaiser Permanente Downey Medical Center, Downey
  • City of Hope Comprehensive Cancer Center, Duarte
  • Loma Linda University Medical Center, Loma Linda
  • dan 13 lagi
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296

MCT for the Harvard/UCSF ROBIN Center

  • University of California, San Francisco, San Francisco
Mengambil peserta
Semua umur · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06000787

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital Los Angeles ( Site 1006), Los Angeles
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • Rady Children's Hospital, San Diego
Mengambil pesertaFasa 2
Sehingga umur 22 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT02559778

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • Rady Children's Hospital, San Diego
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Kaiser Permanente Downey Medical Center, Downey
  • Loma Linda University Medical Center, Loma Linda
  • Children's Hospital Los Angeles, Los Angeles
  • dan 9 lagi
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital of Orange County, Orange
  • UCSF Medical Center-Mission Bay, San Francisco
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • UCSF Benioff Children's Hospital Oakland, Oakland
  • Rady Children's Hospital, San Diego
Mengambil pesertaFasa 2
12 Months – 21 Years · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05489887

SPEARHEAD-3 Pediatric Study

  • Stanford University, Palo Alto
Mengambil pesertaFasa 1/2
Umur 2 hingga 21 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05642455

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Cedars-Sinai Medical Center, Los Angeles
  • University of California, San Francisco, San Francisco
Mengambil pesertaFasa 1/2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06721689

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  • Children's Hospital Los Angeles, Los Angeles
  • UCSF Benioff Children's Hospital, San Francisco
Mengambil pesertaFasa 2
Umur 1 hingga 31 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT06450041

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Lucille Packard Children's Hospital Stanford, Palo Alto
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04901702

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

  • Stanford University, Palo Alto
Mengambil pesertaFasa 1
Umur 2 hingga 30 · Semua jantina · Dikemas kini 7 Mei 2026 · NCT06500819

Neuroblastoma Biology Study

  • Children's Hospital Los Angeles, Los Angeles
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Mengambil pesertaKajian pemerhatian
31 Days – 99 Years · Semua jantina · Dikemas kini 23 Mac 2026 · NCT01587300

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.